GLUCOSE Ireland - English - HPRA (Health Products Regulatory Authority)

glucose

fresenius kabi limited - glucose anhydrous - solution for infusion - 5 %w/w - carbohydrates

GLUCOSE 5% W/V INTRAVENOUS INFUSION Ireland - English - HPRA (Health Products Regulatory Authority)

glucose 5% w/v intravenous infusion

baxter healthcare limited - glucose monohydrate - solution for infusion - 5.0 anhyd %w/v - carbohydrates

Glucose Injection BP Minijet 50%w/v, Solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

glucose injection bp minijet 50%w/v, solution for injection

international medication systems (uk) ltd - anhydrous glucose - solution for injection - 50 percent weight/volume - carbohydrates; glucose

Sodium Chloride 0.45% w/v and Glucose 5.0% w/v Solution for Infusion BP Malta - English - Medicines Authority

sodium chloride 0.45% w/v and glucose 5.0% w/v solution for infusion bp

baxter healthcare limited - glucose, sodium chloride - solution for infusion - glucose 5 percent weight/volume ; sodium chloride 0.45 percent weight/volume - blood substitutes and perfusion solutions

Glucose 5g/100 ml B. Braun Vet Care solution for infusion for cattle, horses, sheep, goats, pigs, dogs and cats Ireland - English - HPRA (Health Products Regulatory Authority)

glucose 5g/100 ml b. braun vet care solution for infusion for cattle, horses, sheep, goats, pigs, dogs and cats

b. braun melsungen ag. - glucose monohydrate - solution for infusion - 5 grams/100 millilitres - i.v. solutions - cats, cattle, dogs, goats, horses, pigs, sheep - electrolytes

5% Glucose New Zealand - English - Medsafe (Medicines Safety Authority)

5% glucose

baxter healthcare ltd - glucose monohydrate 50 g/l - solution for infusion - 5 % - active: glucose monohydrate 50 g/l excipient: water for injection - glucose (5%) intravenous infusions are mainly indicated: whenever non-electrolyte fluid replacement is required. as a vehicle for drug delivery, provided that the added components are compatible with glucose.

Zoledronic Acid Accord zoledronic acid 4mg/5mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

zoledronic acid accord zoledronic acid 4mg/5ml concentrated injection vial

accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.

XELEVIA sitagliptin (as phosphate monohydrate) 25 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xelevia sitagliptin (as phosphate monohydrate) 25 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 32.13 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

XELEVIA sitagliptin (as phosphate monohydrate) 50 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xelevia sitagliptin (as phosphate monohydrate) 50 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

XELEVIA sitagliptin (as phosphate monohydrate) 100 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xelevia sitagliptin (as phosphate monohydrate) 100 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.